FDA warns Orchid Lifesciences over over-the-counter drug testing gaps and weak quality unit.
What happened
FDA reviewed records Orchid Lifesciences submitted after FDA’s January 25, 2023 request for records under section 704(a)(4); this was a records review, not an inspection. FDA said the records did not show adequate identity testing of high-risk ingredients such as glycerin, propylene glycol and sorbitol for diethylene glycol (DEG) and ethylene glycol (EG), and that the quality unit did not adequately approve or reject components. FDA placed the firm on Import Alert 66-40 on March 23, 2023.
What FDA found
The records did not show at least one identity test on each shipment of each lot of high-risk incoming components, including glycerin, propylene glycol and sorbitol solution, using the USP test that detects diethylene glycol and ethylene glycol.
21 CFR 211.84(d)(1)The quality unit did not effectively use its authority to approve or reject components.
21 CFR 211.22(a)
What FDA wants
FDA tells Orchid Lifesciences to respond in writing within 30 working days with what it has done to correct the violations and prevent recurrence. FDA also asks for specific commitments and risk assessments, including DEG/EG test results within 30 calendar days, and says if corrective actions cannot be completed within 15 working days, the firm must state why and give a completion schedule.
Who should pay attention
- brands that buy OTC drug products or toothpaste from this contract manufacturer
- U.S. importers and distributors of OTC drugs
- quality teams auditing high-risk glycerin, propylene glycol or sorbitol suppliers
This is a summary. Read the original letter on fda.gov.